OncoMatch/Clinical Trials/NCT05932212
AK104 for Recurrent or Metastatic Vulvar Cancer
Is NCT05932212 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including AK104 and AK104+ Paclitaxel+Cisplatin or Carboplatin for vulvar cancer.
Treatment: AK104 · AK104+ Paclitaxel+Cisplatin or Carboplatin — This is a multicenter, open-label, phase II clinical study, aiming to the evaluate the efficacy and safety of AK104 (an anti- PD-1 and CTLA-4 bispecific antibody), alone or combined with chemotherapy, in subjects with recurrent or metastatic vulvar cancer not amenable to curative surgery or radiotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Cervical Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: systemic therapy
should have experienced failure on at least one previous systemic therapy, or intolerance to standard therapy
Cannot have received: immune checkpoint inhibitor
Previous treatment with immune checkpoint inhibitors (e.g., anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA-4 antibody, etc.)
Cannot have received: systemic or curative (surgery or radiotherapy) anti-tumor therapy
Systemic or curative (surgery or radiotherapy) anti-tumor therapy within 4 weeks prior to the first administration
Lab requirements
Blood counts
Adequate organ function as assessed in the laboratory tests
Kidney function
Adequate organ function as assessed in the laboratory tests
Liver function
Adequate organ function as assessed in the laboratory tests
Adequate organ function as assessed in the laboratory tests
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05932212 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immune checkpoint inhibitor, systemic or curative (surgery or radiotherapy) anti-tumor therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages